- cafead   Oct 19, 2023 at 10:32: AM
via The Food and Drug Administration gave Intellia Therapeutics (NTLA) the go-ahead to begin a pivotal study of its gene-editing treatment for a deadly heart disease, but NTLA stock reversed its premarket gains.
article source
article source